Colchicine to see if it reduces coronary artery inflammation in people with HIV

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2, randomized, double-blind, multicenter trial enrolling about 90 people with HIV who are at high cardiovascular risk. Participants receive either colchicine 0.5 mg daily or placebo for 96 weeks, and neither they nor the researchers know which treatment is given. The main goal is to measure changes in coronary artery inflammation using coronary CT angiography and the perivascular fat attenuation index, with secondary safety and inflammatory markers monitored over time. The trial builds on prior evidence that colchicine can reduce vascular inflammation in CAD, exploring its potential in people living with HIV. Eligible participants are adults over 50 with stable ART, suppressed HIV, and high ASCVD risk, on stable statin or lipid therapy as applicable, at centers in Spain.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* PWH \> 50 years old
* High cardiovascular risk measured by SCORE-2 \> 5%
* Stable antiretroviral therapy (ART) in the previous six months
* Viral load \< 50 copies/mililiter for at least 1 year. One blip is allowed (Viral load between 20-200 copies/mililiter with a previous and after viral load determinations \< 20 copies per mililiter.
* CD4 cell count \> 350 cells/mm3
* Stable dose of an intermediate or high intensity statin in the previous year (statin dose should not be modified throghout the study unless there is a robust clinical indication). In case the participant does not receive statins, all other hypolipemiants (bempedoic acid, ezetimibe) will need to be at a stable dose as well in the previous year.
* No clinical indication for a change in treatment based on European Society of Cardiology Guidelines
* Written informed consent obtained according to international guidelines and local laws
* Ability to understand the nature of the trial and the trial related procedures and to comply with them

Exclusion Criteria:

* Severe Heart failure defined as LVEF \< 35%.
* Previous MI, stroke or coronary by-pass surgery
* History of non-cutaneus malignancy prior to enrollment
* History of inflammatory bowel disease or chronic diarrhoea
* Renal dysfunctions defined as eGFR \< 50 ml/min or serum creatinine levels \> 1.7 mg/dL
* Severe hepatic impairments defined as a Child-Pugh category C
* Participants with stomach ulcers or gastrointestinal bleeding
* Levels of ALT over five times the upper limit of normal OR levels of ALT over three times the upper limit of normal AND bilirrubin levels over one point five times the upper limit of normal
* Participant is receiving drugs that inhibit the CYP3A4 (e.g. Verapamil, Azithromycin, Clarithromycin, protease inhibitors, cobicistat), CYP2D6 or inhibitors of P-glycoprotein (see section 6.3.2 for more information)
* Participant needs treatment with colchicine for any indication
* Participants with highly elevated hsCRP \> 10 mg/dL at screening
* Women of childbearing potential. For this trial, definitions of nonchildbearing potential includes:
* Permanent sterilisation methods including hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
* Postmenopausal state, defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
* Male participants are considered fertile after puberty unless permanently sterile by bilateral orchiectomy. To prevent pregnancies in female partners of male participants, they must agree to use highly effective contraceptive methods or have practiced sexual abstinence during the treatment period and until the end of relevant systemic exposure, defined as 5 half-lives of the IMP (9 days approximately).
* Known hypersensitivity to the active substances or any of the excipients
* Known iodine contrast allergy with prior history of anaphylaxis
* Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial.

Where it's running

• Hospital Universitario Vall d' Hebron
  Barcelona, Spain Recruiting
• Hospital La Paz
  Madrid, Spain Recruiting
• Fundación Jiménez Díaz
  Madrid, Spain Not yet recruiting
• Hospital Universitario de la Princesa
  Madrid, Spain Not yet recruiting

Study contacts

• Principal investigator: José Ignacio Bernardino de la Serna, MD, PhD — Hospital Universitario La Paz. IdiPAZ
• Study coordinator: José Ignacio Bernardino de la Serna, MD, PhD
• Email: Jose.bernardino@salud.madrid.org
• Phone: (+34) 915683515

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tailored digital support to cut sedentary time in long-term cardiac rehab

  In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.

  Recruiting University of Lisbon · Lisbon, Lisbon District · NCT07910812

• Expanding HIV-positive donor livers for HIV-positive recipients

  This study tests whether liver transplants from HIV-positive donors to HIV-positive recipients are safe regarding opportunistic infections and cancer.

  Recruiting at 2 sites National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 1 other locations · NCT07778459

• Health for Hungary: Long-term blood and health data collection to study aging and disease onset

  This study tests whether routine blood tests plus advanced molecular analyses can help detect the early stages of non-communicable diseases in adults over 40.

  Recruiting at 21 sites Center for Molecular Fingerprinting Research Nonprofit LLC · Balatonfüred and 32 other locations · NCT07743021

• Optimizing HIV Therapy for AIDS-Related Lymphoma Patients

  This study tests whether long-acting HIV medicines given during lymphoma treatment work better at keeping the virus suppressed than standard oral therapy in adults with AIDS-related lymphoma.

  Recruiting Shanghai Public Health Clinical Center · Shanghai, Shanghai Municipality · NCT07727642

• Inulin Prebiotic for Perimenopausal Women with Overweight or Obesity

  This study tests whether 2 weeks of inulin can affect gut and vaginal microbes, heart health, and muscle health in perimenopausal women who are overweight or obese, using a crossover design.

  Recruiting George Washington University · Washington D.C., District of Columbia · NCT07724522

• Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation

  This trial tests the Laplace TTVR System to see if it safely and effectively treats adults with severe tricuspid regurgitation.

  Recruiting at 2 sites Laplace Interventional, Inc · Tulsa, Oklahoma and 1 other locations · NCT07687485

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.